↓ Skip to main content

Cochrane Database of Systematic Reviews

Nicotine for Alzheimer's disease

Overview of attention for article published in Cochrane database of systematic reviews, April 2001
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (83rd percentile)
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

policy
1 policy source
twitter
6 tweeters

Citations

dimensions_citation
27 Dimensions

Readers on

mendeley
94 Mendeley
Title
Nicotine for Alzheimer's disease
Published in
Cochrane database of systematic reviews, April 2001
DOI 10.1002/14651858.cd001749
Pubmed ID
Authors

Jess López-Arrieta, Francisco José FJS Sanz

Abstract

Nicotine is a cholinergic agonist that acts, not only post-synaptically, but also releases pre-synaptic acetylcholine, and in animal models has been shown to reverse spatial memory decline in rats with lesion in the medial septal nucleus and to show recovery on memory in aged monkeys. Nicotine also has effects on other transmitters like serotonin (5HT), dopamine, or GABA. On the other hand, because nicotine has serious adverse effects, especially concerning cardiovascular risks in elderly people, and also on sleep and behavior, there are several important reasons to conduct a systematic review to assess the clinical efficacy and safety of nicotine in patients with AD. The aim of this review is to determine whether there is evidence of beneficial effect, and to assess its safety profile, when nicotine is used for Alzheimer's disease. The Cochrane Controlled Trials Register (Issue 2, 99) was searched using the terms nicotin* and alzheimer*. Three references to trials were deemed suitable for inclusion but are awaiting consideration while the investigators are contacted. All unconfounded, double-blind, randomized trials in which treatment with nicotine patches or administration of nicotine intravenously was administered for more than a day and compared to placebo in people with Alzheimer's disease. As no trials were suitable for inclusion, no data have been extracted or pooled in a meta-analysis. One trial is awaiting consideration, and if included in an update of this review, any available data will be incorporated. The poor quality of the trials did not allow any synthesis of results across studies. However, the data available in trials considered are compatible with nicotine producing harm, no change or improvement. This review is not able to provide reliable evidence that nicotine is a useful treatment for Alzheimer's disease.

Twitter Demographics

The data shown below were collected from the profiles of 6 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 94 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 1%
Spain 1 1%
Iceland 1 1%
Unknown 91 97%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 15 16%
Student > Master 12 13%
Student > Postgraduate 9 10%
Student > Ph. D. Student 8 9%
Other 8 9%
Other 20 21%
Unknown 22 23%
Readers by discipline Count As %
Medicine and Dentistry 22 23%
Psychology 10 11%
Nursing and Health Professions 8 9%
Pharmacology, Toxicology and Pharmaceutical Science 7 7%
Social Sciences 4 4%
Other 16 17%
Unknown 27 29%

Attention Score in Context

This research output has an Altmetric Attention Score of 8. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 January 2019.
All research outputs
#2,818,906
of 17,349,416 outputs
Outputs from Cochrane database of systematic reviews
#5,462
of 11,660 outputs
Outputs of similar age
#32,863
of 197,795 outputs
Outputs of similar age from Cochrane database of systematic reviews
#102
of 205 outputs
Altmetric has tracked 17,349,416 research outputs across all sources so far. Compared to these this one has done well and is in the 83rd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 11,660 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 24.9. This one has gotten more attention than average, scoring higher than 52% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 197,795 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 83% of its contemporaries.
We're also able to compare this research output to 205 others from the same source and published within six weeks on either side of this one. This one is in the 49th percentile – i.e., 49% of its contemporaries scored the same or lower than it.